VEJLE, Denmark—March 7, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, has obtained approval a Research License from Health Canada under the Cannabis Act. The Research License is a key element in NordicCan’s strategy of obtaining the processing license for cannabinoid oral dosage formats from the new R&D and manufacturing facility, Cogent, located south of Vancouver, Canada.
“We are pleased to strengthen our collaboration with our partners in order to develop and manufacture cannabis oral and intra-oral dosage formats that are safe, convenient and pleasurable for the consumer within wellness, medicinal and pharmaceutical applications”, said Julie Malbaek, NordicCan’s CEO.
Malbaek added, “In the past few years, together with our Cannabis Science Center and R&D in Denmark, we have been working on the maturing of the cannabinoid industry through our expertise in designing products that are safe and consumer friendly, based on our convenient and pleasurable patented delivery systems. With the Research License from Health Canada, we can now conduct multiple studies such as sensory evaluation, taste masking and others in Canada. This will result in a greater flexibility for our customers throughout the R&D projects and reducing turnaround times.”
About NordicCan A/S:
NordicCan A/S, a sister company of Fertin Pharma, develops and produces innovative cannabinoid containing products based on unique oral and intra-oral delivery systems. With a health focus, NordicCan defines its business scope within Wellness, Medicinal and Pharmaceutical approved cannabinoid containing formats. Fertin Pharma and NordicCan jointly have access to and mastery of the most comprehensive portfolio of intra-oral delivery systems globally. They own a wide range of patents covering several oral and intra-oral delivery technologies, which offer the patient and consumer efficient, pleasurable and convenient delivery formats.